医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

医学

Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答

Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Inc Personalis 可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答新发表的数据显示，新型复合生物标志物NEOPS

2021年08月03日

武田交出稳健的2021财年第一季度业绩，促使公司加速营收增长并延续其在研产品线发展态势

バイオテクノロジーヘルスケア感染症腫瘍学製薬遺伝学　 TimeLine: 促使公司加速营收增长并延续其在研产品线发展态势武田交出稳健的2021财年第一季度业绩

2021年08月03日

Oscar Wylee Announces 100th Store; Further Expansion Planned

Oscar Wylee Announces 100th Store; Further Expansion Planned

ヘルスケア眼科医療　 TimeLine: Further Expansion Planned Oscar Wylee Announces 100th Store

2021年08月03日

Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

ヘルスケア感染症臨床試験製薬遺伝学　 TimeLine: 154 a Next Generation STARR Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

2021年08月02日

Fabrinet to Announce Fourth Quarter and Fiscal-Year 2021 Financial Results on August 16, 2021

Fabrinet to Announce Fourth Quarter and Fiscal-Year 2021 Financial Results on August 16, 2021

ヘルスケア医療機器眼科医療　 TimeLine: Fabrinet to Announce Fourth Quarter and Fiscal-Year 2021 Financial Results on August

2021年08月02日

Pillar Biosciences Appoints Dr. Eric Lai to its Board of Directors

Pillar Biosciences Appoints Dr. Eric Lai to its Board of Directors

バイオテクノロジーヘルスケア医療機器外科理学療法腫瘍学製薬遺伝学　 TimeLine: Pillar Biosciences Appoints Dr. Eric Lai to its Board of Directors

2021年08月02日

CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration

バイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬遺伝学　 TimeLine: Application Accepted by China’s National Medical Products Administration CANbridge Pharmaceuticals CAN103 Investigational New Drug

2021年08月02日

IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials

IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances Enters Clinical Trials IASO Biotherapeutics World’s First Fully Human

2021年08月02日

Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as Chief Development Officer

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: as Chief Development Officer Overland Pharmaceuticals Appoints Roger Luo Ph.D

2021年08月02日